Modification of crystallization behavior in drug/polyethylene glycol solid dispersions.
The crystallization kinetics of various active pharmaceutical ingredient/polyethylene glycol (API/PEG) solid dispersions has been investigated using wide-angle X-ray diffraction (XRD) and Raman spectroscopy. APIs with different physicochemical properties and crystallization tendency were employed to form solid dispersions with PEG. The crystallization rate of benzocaine (BZC) in BZC/PEG (20/80 wt %) solid dispersions was decreased substantially in comparison to that of the pure API, while the PEG matrix did not affect the crystallization behavior of haloperidol (HLP). The induction time for crystallization of ibuprofen (IBP) and fenofibrate (FNB) in a PEG matrix was decreased relative to the induction times for pure IBP and FNB. For the latter systems, it appears that crystalline PEG acted as a favorable heterogeneous nucleation site. The crystallization behavior of PEG in the API/PEG systems was also affected to different extents, depending on the API studied. These results suggest that PEG can delay, promote or have no influence on the crystallization kinetics of different APIs, and that any effects on crystallization behavior should be investigated in order to be able to produce a solid dispersion with consistent properties.
School of Chemical Engineering, Purdue University, West Lafayette, Indiana 47907, United States.
Qing
Q
Zhu
Michael T
MT
Harris
Lynne S
LS
Taylor
D001566:Benzocaine / Q000737:chemistry; D003460:Crystallization / Q000379:methods*; D011345:Fenofibrate / Q000737:chemistry; D007052:Ibuprofen / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry*; D013059:Spectrum Analysis, Raman; D014961:X-Ray Diffraction
D011092:Polyethylene Glycols; D011345:Fenofibrate; D001566:Benzocaine; D007052:Ibuprofen